Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth

Core Insights - Myriad Genetics reported a 1% year-over-year increase in revenues for Q2 2025, totaling $213.1 million [2] Company Overview - Myriad Genetics is involved in the biotechnology sector, focusing on genetic testing and related services [2] - The company has a model portfolio that includes small and mid-cap stocks, providing deep analysis for investors [2] Financial Performance - The revenue growth of Myriad Genetics is attributed to specific items that occurred during the reporting period [2]